Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
Intended for Healthcare Professionals
British Journal of General Practice

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Clinical Intelligence

Breast cancer survivorship: key issues and priorities of care

Ridhima Iyer and Alistair Ring
British Journal of General Practice 2017; 67 (656): 140-141. DOI: https://doi.org/10.3399/bjgp17X689845
Ridhima Iyer
Royal Marsden Hospital NHS Trust, Sutton.
Roles: Specialist registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alistair Ring
Institute of Cancer Research, Sutton.
Roles: Consultant medical oncologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info
  • eLetters
  • PDF
Loading

INTRODUCTION

Breast cancer is the most common malignancy in women in the UK, with an average lifetime risk of 1 in 8. Although the incidence of the disease has risen by 6% over the last 10 years, mortality rates have steadily fallen, and currently 80% of patients with early breast cancer have a projected survival of >10 years.1 As a result, the number of patients living beyond a breast cancer diagnosis has steadily grown; there were estimated to be 500 000 breast cancer ‘survivors’ in the UK in 2010 but this number is expected to reach 2 million by 2040.2 Once surgery and any chemotherapy and/or radiotherapy treatments are complete, the traditional model of breast cancer follow-up of multiple routine hospital visits has largely been superseded by an ‘open access’ structure, focusing on supporting self-management and patient empowerment. To make such a service successful, it is suggested that each patient should receive a Recovery Package,3 consisting of the following components:

  1. Cancer care review: review by a primary care practitioner within 6 months of a cancer diagnosis to ensure patients know what services are available to them, embedding the principles of self-management at an early stage.

  2. End of treatment summary: outlines treatments completed and priorities for future care, including any planned surveillance (for example, annual mammograms) and advice on symptoms and signs that could indicate recurrence;

  3. Health needs assessment: comprehensive questionnaire completed by the patient, including a concerns checklist, distress thermometer, and care plan;

  4. Health and wellbeing events: group events that provide an opportunity for patients to be educated on issues such as how to maintain a healthy lifestyle and management of long-term consequences of cancer treatment.

These measures should enable rapid and appropriate self-management or self-referral back to a hospital breast unit, but it is also important that GPs are aware of the common problems and concerns affecting this population.

MENOPAUSAL SYMPTOMS

Many breast cancer treatments can induce menopausal symptoms that may be more severe than those of the physiological menopause, and significantly affect quality of life. A variety of approaches can be attempted including acupuncture, cognitive behavioural therapy, antidepressants, and gabapentin. Hormonal replacement therapy should be avoided in women with a history of early breast cancer because this may precipitate recurrence. Urogenital symptoms including atrophic vaginitis can be a particular problem with aromatase inhibitor therapy. Lifestyle modifications may help, such as stopping smoking and avoiding scented hygiene products. Vaginal non-hormonal preparations may also be helpful, but topical oestrogen preparations are best avoided if possible owing to the potential for systemic absorption. Occasionally, menopausal symptoms are so troublesome that women wish to stop their endocrine therapy; in these cases, discussion with the patient’s oncologist as to the risk–benefit trade-off is usually indicated.

BONE HEALTH

Women treated for early breast cancer, particularly those on adjuvant hormone therapies, are at significant risk of osteoporosis and its associated complications. In patients who are pre-menopausal, tamoxifen appears to accelerate annual bone loss by 1–2% only, and therefore these patients do not routinely require bone monitoring or protection. By contrast, aromatase inhibitors (such as letrozole, anastrazole, and exemestane) significantly increase the risk of osteoporosis and associated fracture.4,5 Patients receiving these agents should have a calcium-rich diet, take 1000–2000 IU vitamin D daily and undertake regular weight-bearing exercise. For those with a baseline T score of <2, assessment of bone mineral density should be undertaken every 1–2 years. In the event of >10% loss annually, or 4–5% if the patient was osteopenic at baseline, an oral or intravenous bisphosphonate should be initiated.6

PSYCHOLOGICAL

There is no standard psychological reaction to a diagnosis of breast cancer, and patients vary in their ability and methods of coping. They may struggle with uncertainty, particularly in relation to future recurrence, family and relationship stress, disordered mood including anxiety and depression, and issues around body image. Effective patient-centred communication and a continued focus on supportive self-management are key to detecting and preventing potential psychological problems. In difficult cases, referral for counselling or cognitive behavioural therapy may be helpful.

Some patients report cognitive problems during the time of chemotherapy, including difficulties with word-finding, multitasking, short-term memory, and attention span, and in some cases these persist beyond treatment completion. There is evidence that non-pharmacological intervention, such as cognitive training, exercise, yoga, and mindfulness-based activities, may be helpful in some patients.

FATIGUE

Cancer-related fatigue is poorly understood, but has been reported in 30–50% of breast cancer survivors in the first 5 years after treatment.7 Significant risk factors include chemotherapy and coexistent depression, anxiety, or catastrophising personality, and identifying these at-risk patients early may be helpful. Management may include promotion of physical activity and exercise, acupuncture, cognitive-behavioural interventions, and mind–body interventions such as yoga and massage. Guarana and ginseng may be helpful, but this has not been confirmed in randomised clinical trials.

LOCAL AND REGIONAL CHANGES

Changes in the breast tissue are common in patients who have undergone surgery and adjuvant radiotherapy; these can include breast shrinkage, telangiectasia, pigmentation, and breast swelling. Patients are counselled regarding these changes prior to therapy, but they can nonetheless cause concern, and if there is uncertainty as to the significance of clinical findings, patients should be reassessed at their breast unit.

Breast-cancer-associated lymphoedema is three times more common in patients who have undergone axillary dissection compared with those who had sentinel lymph node biopsy only. Those who have had more nodes removed, mastectomy, or who are overweight are also at higher risk.8 Post-surgery, patients are given advice on how to prevent and treat symptoms, which includes manual lymphatic drainage, compression therapy (sleeves or bandages), and good skin care. All patients should be advised to avoid trauma and venepuncture to the affected arm, to obtain antibiotics promptly if infection develops, and to maintain a healthy body weight.

LONG-TERM IMPLICATIONS OF BREAST CANCER TREATMENT

These include chemotherapy-induced infertility and, in patients who remain fertile, the timing of future pregnancies. Patients may seek advice regarding their options and are likely to merit re-referral to secondary care, as a complex risk–benefit analysis is likely to be involved.

A number of interventions used to treat early breast cancer (anthracycline chemotherapy, radiotherapy, and trastuzumab) increase the risks of cardiotoxicity. This will usually be detected during the active phases of treatment; however, some patients, particularly those with pre-existing risk factors for cardiac disease, may remain at increased risk of cardiac complications (particularly left ventricular failure) in the longer term.

Patients who have treatment for early breast cancer remain not only at risk of recurrence of their breast cancer (at local or metastatic sites) but are also at increased risk of other primary malignancies as a result of the treatment they have received. These include tamoxifen-associated endometrial cancer, radiotherapy-associated lung cancer, and an increased risk of haematological malignancies (myelodysplastic syndrome and acute myeloid leukaemia) owing to chemotherapy exposure.

CONCLUSION

There are clearly many potential implications that a diagnosis and treatment of early breast cancer might have on a patient that may lead them to seek advice and guidance from their primary care physician. Many GPs feel comfortable dealing with these issues, but, where this is not the case, clear communication between breast cancer units and primary care will be essential for the safe and effective care of this large and ever-increasing population of women.

Notes

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Discuss this article

Contribute and read comments about this article: bjgp.org/letters

  • Received October 7, 2016.
  • Revision requested October 31, 2016.
  • Accepted November 4, 2016.
  • © British Journal of General Practice 2017

REFERENCES

  1. 1.↵
    1. Cancer Research UK
    (2015) Breast cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer (accessed 3 Feb 2017).
  2. 2.↵
    1. Maddams J,
    2. Utley M,
    3. Møller H
    (2012) Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer 107(7):1195–1202, doi:10.1038/bjc.2012.366, Epub 2012 Aug 14.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. National Cancer Survivorship Initiative
    (2013) Living with and beyond cancer: taking action to improve outcomes, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/181054/9333-TSO-2900664-NCSI_Report_FINAL.pdf (accessed 3 Feb 2017).
  4. 4.↵
    1. Eastell R,
    2. Adams JE,
    3. Coleman RE,
    4. et al.
    (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051–1057.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Forbes JF,
    2. Cuzick J,
    3. Buzdar A,
    4. et al.
    (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Hadji P,
    2. Aapro MS,
    3. Body JJ,
    4. et al.
    (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546–2555.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Lindley C,
    2. Vasa S,
    3. Sawyer WT,
    4. Winer EP
    (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16(4):1380–1387.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. DiSipio T,
    2. Rye S,
    3. Newman B,
    4. Hayes S
    (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515.
    OpenUrlCrossRefPubMed
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 67 (656)
British Journal of General Practice
Vol. 67, Issue 656
March 2017
  • Table of Contents
  • Index by author
Download PDF
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Breast cancer survivorship: key issues and priorities of care
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Breast cancer survivorship: key issues and priorities of care
Ridhima Iyer, Alistair Ring
British Journal of General Practice 2017; 67 (656): 140-141. DOI: 10.3399/bjgp17X689845

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Breast cancer survivorship: key issues and priorities of care
Ridhima Iyer, Alistair Ring
British Journal of General Practice 2017; 67 (656): 140-141. DOI: 10.3399/bjgp17X689845
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • INTRODUCTION
    • MENOPAUSAL SYMPTOMS
    • BONE HEALTH
    • PSYCHOLOGICAL
    • FATIGUE
    • LOCAL AND REGIONAL CHANGES
    • LONG-TERM IMPLICATIONS OF BREAST CANCER TREATMENT
    • CONCLUSION
    • Notes
    • REFERENCES
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • How to manage low testosterone level in men: a guide for primary care
  • Hyperparathyroidism (primary) NICE guideline: diagnosis, assessment, and initial management
  • The atypical presentation of COVID-19 as gastrointestinal disease: key points for primary care
Show more Clinical Intelligence

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242